Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress by Schug, Zachary T. et al.
s 
 
 
 
Schug, Z. T. et al. (2015) Acetyl-CoA synthetase 2 promotes acetate 
utilization and maintains cancer cell growth under metabolic stress. Cancer 
Cell, 27(1). pp. 57-71.  
 
 
Copyright © 2015 The Authors 
 
 
http://eprints.gla.ac.uk/102643 
 
 
 
Deposited on:  16 February 2015 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
Cancer Cell
ArticleAcetyl-CoA Synthetase 2 Promotes Acetate
Utilization and Maintains Cancer Cell Growth
under Metabolic Stress
Zachary T. Schug,1,8 Barrie Peck,2,8,11 Dylan T. Jones,3 Qifeng Zhang,4 Shaun Grosskurth,5 Israt S. Alam,6
LouiseM. Goodwin,5 Elizabeth Smethurst,4 SusanMason,1 Karen Blyth,1 LynnMcGarry,1 Daniel James,1 Emma Shanks,1
Gabriela Kalna,1 Rebecca E. Saunders,2 Ming Jiang,2 Michael Howell,2 Francois Lassailly,2 May Zaw Thin,2
Bradley Spencer-Dene,2 Gordon Stamp,2 Niels J.F. van den Broek,1 Gillian Mackay,1 Vinay Bulusu,7 Jurre J. Kamphorst,7
Saverio Tardito,1 David Strachan,1 Adrian L. Harris,3 Eric O. Aboagye,6 Susan E. Critchlow,5 Michael J.O. Wakelam,4
Almut Schulze,2,9,10 and Eyal Gottlieb1,*
1Cancer Research UK, Beatson Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK
2Cancer Research UK, London Institute, 44 Lincoln’s Inn Fields, London WC2A 3LY, UK
3Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital,
Oxford OX3 9DS, UK
4Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT, UK
5AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, UK
6Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
7Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK
8Co-first author
9Present address: Theodor Boveri Institute, Biocenter, University of Wu¨rzburg, Am Hubland, 97074 Wu¨rzburg, Germany
10Present Address: Comprehensive Cancer Center Mainfranken, Josef-Schneider-Strasse 6, 97080 Wu¨rzburg, Germany
11Present address: The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London SW3 6JB, UK
*Correspondence: e.gottlieb@beatson.gla.ac.uk
http://dx.doi.org/10.1016/j.ccell.2014.12.002
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARYA functional genomics study revealed that the activity of acetyl-CoA synthetase 2 (ACSS2) contributes to can-
cer cell growth under low-oxygen and lipid-depleted conditions. Comparative metabolomics and lipidomics
demonstrated that acetate is used as a nutritional source by cancer cells in an ACSS2-dependent manner,
and supplied a significant fraction of the carbon within the fatty acid and phospholipid pools. ACSS2 expres-
sion is upregulated under metabolically stressed conditions and ACSS2 silencing reduced the growth of
tumor xenografts. ACSS2 exhibits copy-number gain in human breast tumors, and ACSS2 expression corre-
lates with disease progression. These results signify a critical role for acetate consumption in the production
of lipid biomass within the harsh tumor microenvironment.INTRODUCTION
Under typical cell culture conditions and in many tissues within
the human body, the primary source of lipids for membrane
biogenesis is the plasma. However, exposure to lipid-deplete
conditions causes a highly coordinated reorganization of the
lipid metabolism machinery that is primarily orchestrated bySignificance
Tumors are situated in a metabolically challenging environme
nutrients that come with it, is scarce. We found that nearly 4
acetyl-CoA synthetase 2 (ACSS2). ACSS2, an enzyme that co
advantage under conditions ofmetabolic stress by enhancing t
tional source when other carbon sources are scarce or cannot
identified ACSS2 as a potential molecular target for managingthe sterol regulatory element-binding protein (SREBF) family
of transcription factors, which drive the expression of genes
encoding for enzymes involved in fatty acid and cholesterol
biosynthesis. Deregulated expression of many of these meta-
bolic enzymes is a feature of different disease states, including
cancer. Importantly, de novo lipogenesis is a key component
of anabolic metabolism and is necessary to meet the demandsnt where blood supply, and the supply of oxygen and other
0% of invasive ductal carcinoma have high expression of
nverts acetate to acetyl-CoA, imparts a competitive growth
he ability of cancer cells to use acetate as an additional nutri-
be used to sustain lipid biomass production. This study also
cancer growth.
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unfavorable conditions (Baenke et al., 2013).
Despite knowledge of the relationship between tumor pro-
gression and changes in lipid metabolism (Menendez and
Lupu, 2007), it was not until the early 1990s that fatty acid
synthase (FASN) was strongly associated with recurrence,
metastases, and death in breast cancer patients (Kuhajda
et al., 1994). Subsequently, de novo fatty acid synthesis was
found to be a critical regulator of breast, prostate, and lung
cancer growth (Alli et al., 2005; Orita et al., 2008; Pizer et al.,
1996a, 1996b, 1996c, 2001; Puig et al., 2009; Zhan et al.,
2008). Selective activation of the fatty-acid-synthesis pathway
commonly occurs in many cancer types, and, in particular,
FASN upregulation was identified as an early event during
the development of prostate cancer (Swinnen et al., 2000b,
2002); evidence suggested that this lipogenic phenotype was
driven by SREBF signaling (Swinnen et al., 2000a). Further-
more, RNAi silencing of FASN expression in an androgen-re-
ceptor-positive prostate cancer cell line strongly inhibited
cell proliferation (De Schrijver et al., 2003). It has even been
suggested that FASN itself can be sufficient to drive the trans-
formation of prostate cells and may be a good target for anti-
neoplastic therapy (Migita et al., 2009). Consequently, FASN
has been the subject of drug development efforts, and specific
FASN inhibitors, such as C75 and GSK837149A, have been
developed and shown to kill cancer cells as well as synergize
with established therapies (Menendez and Lupu, 2007). But
crucially, these compounds have been shown to have poor
pharmacokinetics or exhibit target-related toxicities. These
findings support the hypothesis that targeting lipid synthesis
can have a marked effect on cancer growth, but that the cur-
rent selected targets may not be optimal, highlighting the need
for the discovery of additional therapeutic targets that inhibit
lipid metabolism.
The sole carbon source and precursor for both fatty acid and
cholesterol biosynthesis in mammalian cells is acetyl-CoA. The
cytosolic pool of acetyl-CoA is mainly supplied by two different
ATP-dependent reactions: cleavage of citrate into oxaloacetate
and acetyl-CoA by ATP citrate lyase (ACLY) or the ligation of
acetate and CoA by acetyl-CoA synthetase (ACSS). It has
been shown that ACLY is required for cell growth and cancer
cell survival, and there has been interest in the development
of ACLY inhibitors, with some showing potential at inhibiting tu-
mor growth (Beckers et al., 2007; Hatzivassiliou et al., 2005; Zu
et al., 2012). However, only a few studies have addressed the
potential role of acetate in the context of cancer (Yoshii et al.,
2009a, 2009b; Yoshimoto et al., 2001; Yun et al., 2009). There
are three genes that encode ACSS proteins, namely ACSS1,
ACSS2, and a more recently proposed third family member
ACSS3 (Luong et al., 2000; Watkins et al., 2007). ACSSs
were originally identified as SREBF target genes, but relatively
little is known regarding the regulation of ACSS gene expres-
sion (Luong et al., 2000; Schwer et al., 2006; Sone et al.,
2002). Early studies indicated that ACSS activity controlled ac-
etate uptake (Luong et al., 2000; Tucek, 1967). Herein, we at-
tempted to identify lipid metabolism genes that were critical
to the growth and survival of breast and prostate cancer cells
in metabolically stressed conditions, such as hypoxia and low
lipid availability.58 Cancer Cell 27, 57–71, January 12, 2015 ª2015 The AuthorsRESULTS
Exposure to Hypoxia and Low Serum Alters Lipid
Metabolism
It is now widely accepted that de novo lipogenesis is critical to
tumor progression and survival and is driven by the increased
expression of a host of lipogenic enzymes (reviewed by Menen-
dez and Lupu, 2007; Zaidi et al., 2013). We initially characterized
the dependency of breast cancer cell lines on de novo fatty acid
synthesis under high- and low-serum conditions. The FASN in-
hibitor C75 had no effect on breast cancer cell lines when
cultured in the presence of 10% serum (Figure 1A). However,
treatment in low serum reduced cell number in the majority of
the breast cancer cell lines tested. In addition, the IC50 for a
recently developed FASN inhibitor, AZ22, was drastically
improved when cells were cultured in low serum (Figure 1B
and Figure S1A available online).
To delineate changes in the lipid profiles of normoxic versus
hypoxic cancer cells, we performed high-resolution acyl chain
profiling of phosphatidylcholine (PC) and phosphatidylethanol-
amine (PE) using liquid chromatography-tandem mass spec-
trometry (LC-MS/MS)-based lipidomics. We noted a shift in the
profile of PC and PE that was mainly characterized by the pres-
ence of shorter, more saturated acyl chains in hypoxia compared
to normoxia (Figures 1C and S1B). This type of shift is indicative
of increased de novo fatty acid synthesis and elongation, which
produce mainly saturated fatty acyl-CoA and, to a lesser degree,
monounsaturated acyl-CoA (Hilvo et al., 2011; Rysman et al.,
2010; Sahar et al., 2014). Since glucose can contribute to the
synthesis of phospholipids by supplying the glycerol backbone
via glycerol 3-phosphate and also by the production of the fatty
acid precursor acetyl-CoA, we traced the fate of 13C6-glucose
using targeted metabolomics and lipidomics (Figure S1C). It
should be noted that all metabolomics experiments throughout
the entire study used custom-formulated serum-like tissue cul-
ture medium (SMEM) containing concentrations of metabolites
more physiologically relevant to human plasma than what is typi-
cally found in standard growth mediums. Selected metabolite
concentrations were based on the most current literature where
available and also as defined by the NIH (http://www.nlm.nih.
gov/medlineplus/ency/article/003361.htm; Table S1).
A high volume of medium to cell number ratio was maintained
to ensure cells were exposed to concentrations of metabolites
that were still within the reported physiological ranges. For
instance, we found that 20% of available glucose in normoxia
and 40%during hypoxia was consumed during a typical 24 hr in-
cubation (Figure S1D). We also noted that, in normoxia, glucose
was readily used by the tricarboxylic acid (TCA) cycle with >75%
of citrate labeled from glucose; however, under hypoxic condi-
tions, this contribution was decreased 5-fold (Figure S1E). This
was likely due to the well-characterized inactivation of pyruvate
dehydrogenase by pyruvate dehydrogenase kinase 1 under hyp-
oxic conditions (Kim et al., 2006; Papandreou et al., 2006). In
addition, an in-depth analysis of the most abundant PC species
(34:1) detected a high degree of labeling under normoxic condi-
tions (>95%), suggesting that the majority of PC(34:1) had been
synthesized de novo from glucose (Figure S1F). Strikingly, in
hypoxia, there was a sharp decline in the labeling of the fatty
acid component of PC(34:1) (i.e., isotopologs R M+4), but not
Figure 1. In Vivo Conditions Are Most Closely Mimicked by Culturing Cells in Low Serum and Hypoxia
(A) Sensitivity of breast cancer cells to C75 (2.5 mM) treatment in high (10%) and low (1%) serum concentrations. Data are presented as mean ± SEM (n = 3).
(B) pIC50 (log IC50) values for AZ22 in breast cancer cell lines cultured in full serum or lipid-reduced serum. Data are presented as mean ± SEM (nR 3).
(C) Lipid profiling of PC by LC-MS under normoxic (21%) and hypoxic (0.1%) conditions in MDA-MB-468 breast cancer cells grown in low serum. PC species
containing highly polyunsaturated acyl chains (R3 C = C bonds) are underlined. Data are presented as mean ± SEM (n = 3).
(D) DU145, MDA-MB-468, and PC3 spheroids were grown in full medium and in the presence of AZ22 for 8–12 days to determine the dependency of spheroid
growth on de novo fatty acid synthesis. Data are presented as mean ± SEM (nR 3).
(E) Short-term tumor xenograft growth of BT474 cells treatedwith vehicle or AZ62. Tumorswere grown to 100mm3 and size-matched animals were randomized to
AZ62 or vehicle treatment. Animalswere treatedwith AZ62 at 100mg/kg (oral administration) daily for 7 days. Data are presented asmean ±SEM (n = 4 per group).
(F) Steady-state levels of acetyl-CoA and CDP-choline in BT474 tumor extracts as determined by LC-MS-based metabolomics. Data are presented as
mean ± SEM (n = 6 per group).
See also Figure S1 and Table S1.
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results imply that the majority of glycerol within the PC fraction is
generated de novo by the cells, and suggest a strong depen-
dency on biosynthetic pathways (Brockmo¨ller et al., 2012).
Given the observed changes in lipid metabolism and
increased sensitivity to FASN inhibition in hypoxia and low
serum, we next examined whether spheroids and tumor
xenografts, models that naturally generate oxygen and nutrient
gradients, also were susceptible to FASN inhibition. DU145,
MDA-MB-468, and PC3 spheroid cultures treated with AZ22
were all dose-dependently sensitive to FASN inhibition (Fig-
ure 1D). Furthermore, using a different FASN inhibitor (AZ62)
with improved pharmacokinetics and increased tolerance in vivo,
we found that AZ62 inhibited BT474 xenograft tumor growth
(Figures 1E and S1G). Analysis of metabolite extracts from
the AZ62-treated tumors by liquid chromatography-mass
spectrometry (LC-MS) detected elevated levels of the fatty
acid precursor acetyl-CoA and the PC precursor CDP-choline
(Figure 1F).
Altogether, these results indicate that metabolic stress in-
duces major changes in the lipid metabolism landscape of
cancer cells, creating a dependence on de novo lipogenesis
for survival in hypoxia/low serum (Ackerman and Simon, 2014;
Bensaad et al., 2014). The data imply that, despite a high level
of de novo lipogenesis under hypoxia (30%–50% labeled from
glucose via glycerol 3-phosphate), glucose contribution to fatty
acid biosynthesis is markedly decreased and an alternative car-
bon source would be required. Lastly, the growth inhibition
observed in conditions of metabolic stress was recapitulated in
spheroids and tumors, suggesting that tumors are indeed sub-
ject to conditions in which oxygen and lipids are severely limited.
Functional Genomics Identifies ACSS2 as a Critical
Gene for Cancer Cell Survival under Hypoxic or Low-
Serum Conditions
Expression of many genes involved in lipid biosynthesis is
induced in response to activation of SREBF by the PI3K/Akt/
mTORC1-signaling axis (Porstmann et al., 2008), which is
frequently deregulated in human cancer. Furthermore, 50% of
genes predicted to be highly significant for increasing the
biomass of cancer cells by a genome-scale metabolic modelFigure 2. ACSS2 Is Frequently Upregulated in Cancer and Positively C
(A) Proportional phenotypic classification of siRNA target genes.
(B) Top hits from screening under metabolic stress. Growth data are presented as
mean ± upper and lower limits (n = 3) (black bars, right y axis) and are normalize
(C) Representative immunohistochemistry images of ACSS2 expression from a t
(D) Histograms illustrating ACSS2 expression in normal adjacent breast tissue (N
significant; n = 75).
(E) ACSS2 DNA copy-number variation comparing normal and IDC samples (p v
lower quartiles, the band represents the median, and the whiskers represent 5–9
(F) ACSS2 mRNA expression at different stages of IDC (asterisk, p < 0.05, Dunne
band represents the median, and the whiskers represent 5–95th percentile.
(G) ACSS2 mRNA expression in invasive carcinoma and the patient survival st
represent the upper and lower quartiles, the band represents the median, and th
(H) Representative immunohistochemistry images of ACSS2 expression from a t
(I) Histogram illustrating ACSS2 expression in normal tissue and primary and me
(J) The p values and fold change showing increased ACSS2 expression in metas
from the Grasso (left) and Chandra (right) prostate cancer data sets available from
the median, and the whiskers represent minimum and maximum (p values are in
See also Figure S2 and Tables S2, S3, and S4.of cancer were associated with lipid metabolism (Folger et al.,
2011). Based on these independent lines of evidence, we
assembled a small interfering RNA (siRNA) library of 66 potential
targets with gene ontologies associated with lipid metabolism
(Figure 2A; Tables S2 and S3). Functional genomics screens
were performed using eight breast and three prostate cancer
cell lines (Table S4). Based on our preliminary results with
FASN inhibitors (Figure 1), we investigated growth inhibition
during metabolic stress: 1% serum in normoxia, 10% serum in
hypoxia, and 1% serum in hypoxia compared to the nutrient-
and oxygen-rich conditions of 10% serum in normoxia. A strictly
standardized mean difference (SSMD) was used to evaluate the
potency and selectivity of silencing on growth relative to an inter-
nal nontargeting control (Zhang, 2011; Table S4). This prelimi-
nary filter was used to rank targets according to the difference
in growth inhibition when comparing normoxia to hypoxia or
10% serum to 1% serum conditions (Table S4). The top targets
from the screen were reassessed using a different pool of
siRNAs (Figure 2B; Table S4). Following siRNA pool deconvolu-
tion of all the shortlisted targets, we found the top hits for hypoxia
and low serum were, respectively, acetyl-CoA synthetase 2
(ACSS2) and stearoyl-CoA desaturase (SCD) (Figure 2B).
We next performed a comprehensive data mining analysis of
the expression and disease association of the targets that
passed deconvolution. ACSS2 had the highest frequency of
DNA copy-number gain in breast tumors and was associated
with increased ACSS2 expression (Figures S2A and S2B). The
relatively focal ACSS2 amplicon, which contains 47 other genes,
spans most of the genomic region encompassing 20q11.22 and
does not include any cancer consensus genes (Figures S2C and
S2D). In support of the expression data from publically available
patient data sets, immunohistochemical staining of tumor micro-
arrays revealed high ACSS2 expression in nearly 40%of invasive
ductal carcinomas (IDCs) compared to their normal adjacent
tissue samples, with a similar trend observed in invasive lobular
carcinomas (ILCs) (Figures 2C and 2D). Focused datamining of a
separate breast cancer database noted a significant increase in
ACSS2 copy number in cancer versus normal tissue (Figure 2E;
Curtis et al., 2012). There was also a strong correlation between
ACSS2 expression and disease progression (Figure 2F; Curtis
et al., 2012). A Dunnet’s multiple comparison test between stageorrelates with Disease Progression and Poor Survival
mean ± SD (white bars, left y axis) andmRNA expression data are presented as
d to a nontargeting control siRNA pool.
issue microarray of breast cancer samples.
AT, n = 12) and (left) IDC (p value = 0.0295; n = 78) and (right) ILC (NS = not
alue = 1.0 3 104, unpaired, two-tailed t test). Boxes represent the upper and
5th percentile.
t multiple comparison test). Boxes represent the upper and lower quartiles, the
atus at 1 and 5 years (Mann-Whitney test, p values are as indicated). Boxes
e whiskers represent 10th–90th percentile.
issue microarray of prostate cancer samples.
tastatic prostate cancers.
tatic prostate cancer compared with primary site tumors. Data were obtained
Oncomine. Boxes represent the upper and lower quartiles, the band represents
dicated, unpaired, two-tailed t test).
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Figure 3. Metabolic Stress Induces Upregu-
lation of ACSS2 and Causes Cells to
Become Increasingly Sensitive to ACSS2
Depletion
(A) BT474 and DU145 cell counts at 96 hr post-
siRNA transfection. Dotted line represents the
seeding density. Data are presented asmean ± SD
(n = 3).
(B) ACSS2 mRNA expression in BT474 and DU145
cells under metabolic stress (hypoxia = 0.1% O2).
Error bars represent SEM (n = 2).
(C) ACSS2 protein expression in BT474 and
DU145 cells under metabolic stress.
(D) ACSS2 mRNA expression in BT474c1 cells
expressing an shRNA against ARNT. Data are
normalized to expression of shNTC in normoxia +
10% serum. Error bars represent SEM (n = 3).
(E) ACSS2 mRNA expression in BT474c1 cells
transfected with a nontargeting control siRNA or a
pool of siRNAs against SREBF1 or SREBF2. Data
are normalized to expression of siNTC in 10%
serum and normoxia (hypoxia = 0.1% O2). Error
bars represent SEM (n = 3).
See also Figure S3.
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ACSS2 in stages 2, 3, and 4, and a test of linear trend further
confirmed a systematic increase in ACSS2 expression with
escalating tumor stage (p = 0.0001) (Figure 2F). Using this
same data set, we further noted that ACSS2 expression was
significantly higher (p < 0.05; Mann-Whitney test) in patients
who did not survive past 1 or 5 years postdiagnosis (Figure 2G).
In prostate cancer patients, there was an increased expression
of ACSS2 in metastasis compared to primary tumor or normal
tissue (Figures 2H and 2I). These results were consistent with ob-
servations from two different publically available prostate cancer62 Cancer Cell 27, 57–71, January 12, 2015 ª2015 The Authorsdata sets, suggesting that ACSS2 may
be particularly important in more aggres-
sive prostate cancers and metastases
(Figure 2J).
Hypoxia and Low-Serum Culture
Conditions Synergistically Enhance
ACSS2 Expression
The Cancer Cell Line Encyclopedia was
used to identify breast cancer cell lines
with strong evidence for ACSS2 copy-
number gain and upregulation (Barretina
et al., 2012; Forbes et al., 2011; Shao
et al., 2013). Two of the cancer cell lines
used in the functional screen had high
ACSS2 expression, namely MDA-MB-
468 and SKBr3, while BT474 had the
overall highest level of DNA copy-number
gain and expression (Figures S3A and
S3B). DNA copy-number gain for both
the 20q arm and 20q11 chromosomal
band, containing ACSS2, has been re-
ported previously for BT474 and SKBr3,
as detected by fluorescence in situ hy-bridization, genomic hybridization, and comparative genomic
hybridization array (Brinkmann et al., 1996; Guan et al., 1996;
Pinkel et al., 1998; Rondo´n-Lagos et al., 2014). Given the
enhanced growth inhibition observed by ACSS2 silencing during
the functional screening in hypoxia, we measured ACSS2-
dependent growth during metabolic stress. Silencing of ACSS2
was most effective at growth inhibition under metabolic stress
and, interestingly, was cytotoxic to BT474 cells (Figures 3A
and S3C). Furthermore, expression analysis of our panel of can-
cer cell lines revealed consistent upregulation of ACSS2 at both
the mRNA (Figures 3B, S3D, and S3E) and protein levels
Cancer Cell
Acetate Metabolism under Metabolic Stress(Figure 3C) under metabolic stress. These results reinforced
the hypothesis that ACSS2 becomes important for cell prolifera-
tion under metabolic stress and that cancer cells harboring
ACSS2 copy-number gains may be more vulnerable to ACSS2
depletion.
A test for mutual exclusivity among 962 breast cancer samples
(The Cancer Genome Atlas) revealed a significant tendency to-
ward co-occurrence between ACSS2 and hypoxia-inducible
transcription factor (HIF) targets LDHA and PDK1, suggesting it
may be a HIF target (Figure S3F). Indeed, small hairpin RNA
(shRNA)-mediated silencing of ARNT expression reduced the
upregulation of ACSS2 by 2.5-fold (Figures 3D and S3G). How-
ever, unlike the complete loss of hypoxia-induced upregulation
of LDHA and PDK1 noted after ARNT silencing, some ACSS2
upregulation persisted (Figures 3D and S3H). Since ACSS2 is
known to be a target of SREBF signaling (Luong et al., 2000)
and SREBFs are activated by lipid depletion (Briggs et al.,
1993; Wang et al., 1993), it seemed likely that ACSS2 expression
would be controlled by SREBFs. Silencing of SREBF2, but
not SREBF1, completely eliminated the upregulation of ACSS2
under conditions of metabolic stress (Figures 3E and S3I).
Together, the expression data imply that SREBF2 mainly con-
trols ACSS2 expression, but that ARNT-dependent HIF signaling
enhances the upregulation of ACSS2 by SREBF2. Interestingly,
the expression of FASN was highly upregulated under metabolic
stress and controlled in exactly the same manner as ACSS2,
suggesting the two targets are intimately linked (Figure S3J).
Acetate Supports Biosynthesis of Membrane
Phospholipids
The molecular function of ACSS2 is to ligate acetate with coen-
zyme A in an ATP-dependent reaction to produce acetyl-CoA, a
metabolite central to a range of cellular processes (Figure 4A).
We investigated if acetate contributed to the acetyl-CoA pool
and, furthermore, if it was used for lipid synthesis. To that end,
BT474c1, a more tumorigenic subclone of BT474, was used.
BT474c1 cells, which express similar levels of ACSS2 as their
parental cells (Figure S3B), had increased 14C2-acetate uptake
under hypoxic conditions (Figure 4B). Also, 14C2-acetate-depen-
dent fatty acid synthesis increased during metabolic stress (Fig-
ure 4C). However, in all cell lines tested, the steady-state levels of
acetyl-CoA were much lower in hypoxia (Figure 4D).
To investigate this further, we traced the incorporation of 13C2-
acetate into the acetyl-CoA pool and found that, at most, 10%
was labeled during normoxic and lipid-replete growth condi-
tions, while during metabolic stress, over 50% of the acetyl-
CoA pool was labeled by acetate over a 12 hr period (Figure 4E).
The mutual mRNA regulation of ACSS2 and FASN suggested
acetate was being used to support membrane phospholipid
biosynthesis during metabolic stress. To study this, we em-
ployed LC-MS/MS-based lipidomics to trace the incorporation
of 13C2-acetate into the PC(34:1) during metabolic stress. There
was a rightward shift of the PC-isotopolog-labeling pattern, indi-
cating that a higher percentage of PC carbon was sourced from
acetate during metabolic stress than normal growth conditions
(Figure 4F). This shift is highly indicative of an increased availabil-
ity of acetate-derived acetyl-CoA for fatty acid synthesis, and,
importantly, shows that acetate can be a major nutritional
source.ACSS2 Controls Acetate Uptake and Contribution to
Fatty Acids
Previous reports had suggested that acetate consumption is
dictated by functional expression of ACSS2 (Luong et al.,
2000; Tucek, 1967). Measurement of [3H]-acetate uptake in
BT474c1 cells, as well as DU145 prostate cancer cells, demon-
strated reduced acetate consumption after ACSS2 depletion
(Figures 5A and 5B). Interestingly, BT474c1 cells that expressed
high levels of ACSS2 exhibited almost twice asmuch acetate up-
take compared to DU145 cells that expressed low levels of
ACSS2 (Figures 5B and S3B). We further investigated for signs
of inhibition of lipid synthesis by quantifying the substrate of
the final enzymatic reaction in the synthesis of PC and PE (Fig-
ure 5C). Similar to the results using FASN inhibitors (Figure 1F),
CDP-choline and CDP-ethanolamine steady-state levels were
elevated upon ACSS2 silencing, suggesting impairment of de
novo lipogenesis (Figure 5D). Since serum is a source of lipids,
growth factors, and other nutrients, we reassessed ACSS2-
dependent growth in lipid-depleted serum (LPDS) to ascertain
if the observed growth effects during hypoxia, such as seen in
Figure 3, were due to the loss of extracellular lipids or another
component in the serum. Cells grown in 10% LPDS were more
sensitive to ACSS2 silencing than cells grown in 10% full serum
in hypoxia (Figure 5E). Similar to 1% serum, 10% LPDS also
induced ACSS2 expression in hypoxia (Figure 5F).
The most highly characterized pathway of acetate metabolism
concerns the conversion of acetate to acetyl-CoA and the use
of 2-carbon acetyl units to synthesize fatty acids through
successive rounds of condensation by FASN (Roncari, 1974,
1975). We investigated if acetate was being used as an anabolic
precursor for de novo fatty acid synthesis. The concentration of
plasma acetate in humans varies between 0.05 and 0.25 mM
(Scheppach et al., 1991; Skutches et al., 1979; Tollinger et al.,
1979), but can increase up to 1 mM after alcohol consumption
(Lundquist et al., 1962; Tsukamoto et al., 1989). The acetate con-
centration in mouse and rat plasma ranges between 0.20 and
0.30 mM (Kimura et al., 2013; Maxwell et al., 2010). The acetate
concentration in media + 10% serum was measured by gas
chromatography-mass spectrometry and determined to be
0.10 mM (Table S1). Besides exogenous sources, acetate can
be produced endogenously via protein deacetylation. However,
we and others observed that histone acetylation is induced un-
der hypoxia indicating that deacetylation is unlikely an acetate
source during metabolically stressed conditions (Vaapil et al.,
2012; Watson et al., 2009; our unpublished observations).
Initially, we characterized the contribution of 13C2-acetate to
fatty acid synthesis by comparing the isotopolog-labeling
pattern of palmitate and stearate during metabolic stress. LC-
MS-based analysis of palmitate revealed small dose-dependent
differences in acetate-dependent palmitate synthesis as the
concentration of acetate increased from 0.10 to 0.50 mM (Fig-
ure 5G). Similar to the PC-isotopolog-labeling pattern in Figure 4,
there was an overall shift in the abundance of isotopologs <M+8
to R M+8 when cells were exposed to metabolic stress, sug-
gesting increased availability of acetate-derived acetyl-CoA for
fatty acid synthesis (Figure 5G). Similar results were obtained
for stearate (Figure S4A). In addition, silencing of ACSS2 strongly
impaired both palmitate and stearate labeling from acetate (Fig-
ures S4B and S4C).Cancer Cell 27, 57–71, January 12, 2015 ª2015 The Authors 63
Figure 4. Metabolic Stress Increases Acetate Uptake and Supports Biosynthesis of Membrane Phospholipids
(A) Schematic for the ACSS2 reaction and destinations for nucleocytosolic acetyl-CoA.
(B) 14C2-acetate uptake under metabolic stress. Data are presented as mean ± SEM (n = 3).
(C) 14C2-acetate-dependent lipid synthesis over a 12 hr period under metabolic stress. Data are presented as mean ± SEM (n = 3).
(D) Steady-state acetyl-CoA levels in a panel of breast cancer cell lines. Data are presented as mean ± SD (nR 3).
(E) Enrichment of 0.20mM 13C2-acetate in the acetyl-CoA pool in BT474c1 cells cultured in normoxia and SMEM+ 10%serum or hypoxia and SMEM+ 1%serum
over a 12 hr period. Data are presented as mean ± SEM (nR 3).
(F) Abundance of PC(34:1) isotopologs in BT474 cells cultured in SMEM+ 1% serum supplemented with 0.50 mM 13C2-acetate. Area under the curve is shown to
highlight the shift in the isotopolog-labeling pattern induced by metabolic stress. Data are presented as mean ± SEM (nR 2).
Cancer Cell
Acetate Metabolism under Metabolic StressWe next traced the fate of 13C2-acetate within the TCA cycle
by looking at the isotpolog-labeling pattern of citrate. However,
this would be controlled mainly by the other ACSS isoform,
ACSS1, which has been shown to be localized to the mitochon-
dria (Fujino et al., 2001). ACSS1 activity did slightly compensate64 Cancer Cell 27, 57–71, January 12, 2015 ª2015 The Authorsfor silencing of ACSS2 under normoxic conditions, in which an
active TCA cycle was still running (Figure S4D). This was shown
by the increase in M+2 and M+3 labeling of citrate following
ACSS2 silencing in normoxia (Figure S4D). However, under hyp-
oxic conditions, the compensation by ACSS1 was compromised
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Acetate Metabolism under Metabolic Stress(Figure S4D). This is in line with the observation that ACSS1
mRNA expression was downregulated during hypoxia, which
is completely opposite to the mRNA regulation of ACSS2
(Figure S4E).
Subsequently, we supplied cells with 13C6-glucose,
13C5-
glutamine, or 13C2-acetate to compare the relative contributions
of these important nutritional sources to palmitate synthesis. In
normal growth conditions, glucose was the main source for fatty
acid synthesis, followed closely by acetate (Figure 5H). In
contrast, metabolic stress switched the preferred nutritional
source to acetate and completely abrogated the contribution
from glucose (Figure 5H). As previously reported, there was an
increase in glutamine-labeled palmitate during hypoxic condi-
tions (Figure 5H; Filipp et al., 2012; Metallo et al., 2012; Mullen
et al., 2012; Wise et al., 2011). However, neither glucose nor
glutamine, whether in normal growth conditions or low oxygen
and low serum, ever labeled palmitate as extensively as acetate
did during metabolic stress.
ACSS2 Silencing Inhibits Spheroid and Tumor Growth
DU145 + shNTC and DU145 + shACSS2#64 cells were cultured
as spheroids in 10% or 1% serum and in the presence or
absence of doxycycline. Expression of shACSS2 by doxycycline
decreased ACSS2 expression and caused significant growth
inhibition, which was more pronounced under low-serum condi-
tions (Figure 6A). We had observed previously that acetate
was being used to generate lipids (Figures 4 and 5). In addition,
the FASN inhibitor studies and spheroid growth after ACSS2
silencing prompted us to investigate the in vivo efficacy of
ACSS2 silencing on tumor growth and survival. For this we
also generated a BT474c1 cell line expressing inducible shRNA
targeting ACSS2 (Figure 5A). Nude mice were injected subcuta-
neously with DU145, MDA-MB-468, and BT474c1 cells express-
ing ACSS2 shRNA or a nontargeting control or empty vector. All
three xenograft models displayed decreases in tumor growth
when ACSS2 was silenced (Figures 6B, 6C, S5A, and S5B).
Gene silencing was confirmed by immunohistochemistry or
quantitative RT-PCR (qRT-PCR) (Figures 6D, S5C, and S5D).
We also noted that, by the end of the xenograft studies, all
mice bearing tumors depleted of ACSS2 (i.e., +DOX) were still
viable, while nontreated or vector control mice exhibited higher
mortality rates, which were not necessarily associated with
tumor burden (Figure 6E).
Our previous results suggested that ACSS2 expression was
often upregulated under hypoxic conditions (Figure 3). To
examine this in vivo, serial sections from three separate
BT474c1 + shACSS2#20 (no DOX) tumors were stained with pi-
monidazole, a hypoxia-selective marker, and ACSS2. Indeed,
costaining was observed, indicating that hypoxic tumor regions
have significantly higher levels of ACSS2 compared to nonhy-
poxic regions (Figures 6F and 6G). Together, these results
confirm that ACSS2 is upregulated in areas of hypoxia in tumors
and required for efficient growth and survival of cancer cells
in vivo.
DISCUSSION
Hypoxia is a common feature of tumors that have a poor clinical
prognosis and display aggressive traits, such as increased met-astatic and migratory potential, chemoresistance, and stem-
ness. We also know that lipid metabolism is altered drastically
under these conditions (Ackerman and Simon, 2014). Our initial
studies identified that most breast and prostate cancer cell lines
were sensitive to fatty acid synthesis inhibition when cultured as
spheroids or grown as tumor xenografts. However, the only tis-
sue culture condition that faithfully preserved this sensitivity
was when cells were grown under metabolic stress, thus,
strongly suggesting that many cancer cells find a means to sur-
vive and proliferate regardless of poor nutrient delivery and
hypoxia.
The functional screens and in-vivo-induced silencing of
ACSS2 in tumor xenografts highlighted the essentiality of
ACSS2 under metabolically stressed conditions. The metabolic
and lipidomic analyses revealed a mechanistic solution for the
need of acetate and ACSS2 in cancer cells by demonstrating
that, under tumor-like tissue culture conditions, there is a switch
in nutrient utilization from glucose to acetate to support fatty
acid and lipid biosynthesis. In support of this mechanism, we
found that ACSS2 was indeed significantly upregulated in hyp-
oxic regions of tumor xenografts and when cancer cells were
exposed to prolonged oxygen and lipid withdrawal. ACSS2
expression was transcriptionally controlled by a synergistic
interaction between HIF and SREBF2 signaling. In addition,
copy-number gain of ACSS2 was observed in breast carci-
noma, and the lack of cancer consensus genes and the size
of the narrow amplicon region suggested selection pressure.
The data mining information was supported by results from
examining tissue microarrays showing that ACSS2 was highly
expressed in IDCs, the most common histological breast cancer
subtype. Likewise, increased ACSS2 expression seemed to be
more closely associated with prostate metastasis than in pri-
mary tumors.
Our observed link between acetate metabolism and tumor
growth coupled with the knowledge that the primary source of
acetate production within the body is by the intestinal microbiota
compelled us to investigate if there was a potential link between
colorectal cancers and ACSS2. Further cancer data mining
revealed copy-number gain or upregulation of ACSS2 in more
than a quarter of all colorectal cancer (data not shown). If
ACSS2 silencing proves to be effective at inhibiting colorectal
tumor growth, it may reveal a disease in which ACSS2 would
be an attractive target for future drug discovery. Furthermore,
in cells with active lipid biosynthesis, acetate is converted to
acetyl-CoA in the cytosol and then incorporated into fatty acids.
Therefore, radiolabeled acetate is the most lipid-specific tracer
available for positron emission tomography (PET) imaging. Ace-
tate-based PET tracers are established clinical tools, but to date
there is not enough information on how this tracer reflects pertur-
bations in lipid biosynthesis in cancer cells (Lewis et al., 2014;
Oyama et al., 2002; Yun et al., 2009).We have identified a depen-
dency of breast cancers and prostate cancer on acetate meta-
bolism and ACSS2 activity. This presents an attractive opportu-
nity to use tracer technology to identify tumors that would be
responsive to ACSS2-targeted therapy. Moreover, as acetate
uptake is coupled to ACSS2 activity, acetate PET tracers could
provide an important pharmacodynamic biomarker for treatment
response and for detecting when tumors become refractory to
treatment.Cancer Cell 27, 57–71, January 12, 2015 ª2015 The Authors 65
Figure 5. Acetate Is the Major Contributor to Palmitate Synthesis during Metabolic Stress
(A) Immunoblot of BT474c1 and DU145 protein extracts 72 hr postdoxycycline administration.
(B) Uptake of [3H]-acetate in BT474c1 and DU145 cells after doxycycline induced silencing of ACSS2. Cells were cultured in 10% serum and normoxia. Data are
presented as mean ± SEM in triplicate (n = 2).
(legend continued on next page)
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Acetate Metabolism under Metabolic StressIn conclusion, this study highlights the importance of under-
standing the context-dependent metabolic rewiring of cancer
cells in vivo, and provides evidence that acetate is a fundamental
nutrient that can fuel cancer growth. The therapeutic feasibility
of pharmacologically targeting ACSS2 is currently being
explored.
EXPERIMENTAL PROCEDURES
Cell Culture
LNCaP were obtained from the American Type Culture Collection. BT474c1
cells were a kind gift from Jose Baselga. All other cell lines were from the
London Research Institute (CRUK) cell services. DU145, LNCaP, and PC3
cell lines were grown in RPMI supplemented with either 10% or 1% fetal
calf serum (PAA Laboratories), 2 mM L-glutamine, and penicillin/strepto-
mycin. MCF7, BT20, BT474, BT474c1, BT549, MDA-MB-231, MDA-MB-
468, SkBr3, and T47D cell lines were grown in Dulbecco’s modified Eagle’s
medium (DMEM)/F12 with either 10% or 1% fetal calf serum (PAA Labora-
tories), 2 mM L-glutamine, and penicillin/streptomycin. MCF10a and
MCF10A + HER2 (a kind gift from Dr. Zachary Schafer) cells were grown in
DMEM/F12 with either 5% or 0.5% horse serum with 20 ng/ml epidermal
growth factor, 5 mg/ml hydrocortisone, 10 mg/ml insulin, and 100 ng/ml
cholera toxin.
Antibodies and Reagents
ACSS2 (AceS1) antibody (D19C6) and FASN were purchased from Cell
Signaling Technology. Antitubulin, antiactin, anti-ACSS1 (HPA043228), and
anti-ACSS2 (HPA004141) antibodies were purchased from Sigma-Aldrich.
HypoxyProbe kit, including pimonidazole, was purchased from Chemicon
International. All chemicals were purchased from Fisher Scientific or
Sigma-Aldrich. The 13C-labeled metabolites were purchased from Cam-
bridge Isotopes, and 14C-labeled and 3H-labeled acetate were purchased
from PerkinElmer. Secondary antibodies were purchased from LI-COR
Biosciences.
Spheroid Growth Assay
For spheroid formation, cells were trypsinized, counted, mixed with 2% ma-
trigel in culture medium, and placed in 96-well ultralow attachment plates
(Costar). Spheroid formation was initiated by centrifugation at 850 3 g for
10 min, and cultures were incubated for the times indicated. Fresh growth
medium, containing either ethanol or doxycycline (0.5 mg/ml), was adminis-
tered every 48 hr. Spheroid size was determined at the times indicated by
automated imaging on an inverted microscope (Axiovert 100M, Carl Zeiss).
Xenograft Experiments
Female BALB/c nude mice (Charles River Laboratories) were injected sub-
cutaneously with BT474, BT474c1, DU145, or MDA-MB-468 cells and al-
lowed to establish for 1 week. When BT474 or BT474c1 cells were
used, mice were implanted with 17-beta-estradiol 0.36 mg/pellet 24 hr
prior to injection of cells. For shRNA induction, animals were given a doxy-
cycline-containing diet (Harlan Laboratories) or doxycycline-supplemented
drinking water, and tumor growth was followed for the indicated time
period. Tumor volume was determined by caliper measurements and the(C) Schematic representation of the final reaction in the synthesis of PC and PE.
(D) Change in the steady-state intracellular levels of CDP-choline and CDP-ethano
in SMEM + 1% serum and hypoxia (0.1% O2). Data are presented as mean ± SE
(E) BT474c1 cells were transfected with indicated siRNAs for 24 hr prior to the
(0.1% O2). Cell counts were performed 72 hr later. Data are normalized to a non
triplicate (n = 1).
(F) Immunoblot for ACSS2 expression in cell lysates from the experiment in (E).
(G) 13C2-acetate-dependent labeling of palmitate in indicated growth conditions
(H) 13C6-glucose-,
13C5-glutamine-, and
13C2-acetate-dependent labeling of palm
glucose, glutamine, and acetate were equal in all three conditions. Data are pres
See also Figure S4.ellipsoidal volume formula: ½ 3 length 3 width2. Where available, tumor
burden also was determined using bioluminescence imaging at indicated
times. Mice were maintained in individually ventilated cages with environ-
mental enrichment. All procedures were performed with anesthetic and
postoperative analgesics under the Animal (Scientific Procedures) Act
1986 and the EU Directive 2010. Animal experiments at Imperial College
London were carried out under UK Home Office Project License 70/7177
(E.O.A.) with ethical approval from Imperial College London within a Desig-
nated Establishment under the Act (the Central Biomedical Services Unit
at Imperial College London). Animal experiments at the London Research
Institute were performed under UK Home Office Project License 80/2330
(A.S.) after approval by a local ethics committee. Animal experiments at
the Beatson Institute were performed under UK Home Office Project Li-
cense 60/4181 (K.B.) and carried out with ethical approval from University
of Glasgow.
LC-MS
Cells were plated onto 12-well plates and cultured in standardmediumDMEM/
F12 + 10% fetal bovine serum and 2 mM glutamine. Medium was replaced for
specified periods with fresh physiologically relevant medium containing amino
acid concentrations as dictated by http://www.nlm.nih.gov/medlineplus/ency/
article/003361.htm. In addition, all heavy carbon labeling was done using final
concentrations of 5.5 mM glucose, or 0.65 mM glutamine, and 0.10–0.50 mM
acetate. Metabolites were extracted with a cold solution (20C) composed of
methanol, acetonitrile, and water (5:3:2). The insoluble material was immedi-
ately pelleted in a cooled (0C) centrifuge at 16,000 3 g for 15 min, and the
supernatant was collected for subsequent LC-MS analysis. The protein con-
centration in each well was calculated using a Lowry assay. Alternatively, a
separate plate was seeded in parallel and used for cell counts. A ZIC-pHILIC
column (4.6 3 150 mm, guard column 2.1 3 20 mm, Merck) was used for
LC separation using formic acid, water, and acetonitrile as component of the
mobile phase. Metabolites were detected using Thermo Exactive mass spec-
trometer (Thermo Fisher Scientific).
For lipidomic studies, cells were incubated in media containing 5.5 mM
13C6-glucose for 24 hr prior to lipid isolation. Cell pellets were washed twice
with cold degassed PBS and resuspended in methanol before transfer to
silanized glass tubes on dry ice to Babraham Lipidomics Facility for lipid
extraction and analysis. Samples were spiked with 400 ng 12:0/12:0-PC,
100 ng 17:0-LPC, 300 ng 12:0/12:0-PE, and 100 ng 17:1-LPE; 0.88% NaCl;
and chloroform. The mixture was vortexed for 20 s at room temperature and
sonicated in an ice-cold water bath for 2 min. Samples were centrifuged at
1,100 rpm at 4C for 15 min. The lower phase was collected. The upper phase
was extracted with synthetic lower phase (mix chloroform/methanol/0.88%
NaCl at volume ratio of 2:1:1, after phase separation, take the lower phase
as synthetic lower phase for second extraction of lipid). The resulting lower
phase was combined and dried under vacuum at room temperature with
SpeedVac (Thermo Scientific) and redissolved in chloroform. The final product
was injected for LC-MS/MS analysis using a Thermo Orbitrap Elite system
(Thermo Fisher Scientific) hyphenated with a five-channel online degasser,
four-pump, column oven, and autosampler with cooler Prominence HPLC sys-
tem (Shimadzu) for lipids analysis. In detail, lipid classes were separated on a
normal-phase silica gel column (2.13 150 mm, 4micro, MicoSolv Technology)
with hexane/dichloromethane/chloroform/methanol/acetanitrile/water/ethyl-
amine solvent gradient based on the polarity of head group. High resolution
(240k at m/z 400)/accurate mass (with mass accuracy < 5 ppm) and tandemlamine following transfection of the indicated siRNAs in BT474c1 cells cultured
M (n = 3).
addition of 1% serum, 10% serum, or 10% LPDS and transferred to hypoxia
targeting siRNA control for each condition and represent the mean ± SEM in
after 24 hr. Data are presented as mean ± SEM (n = 3).
itate in indicated growth conditions after 24 hr. The relative concentrations of
ented as mean ± SEM (n = 3).
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Figure 6. Silencing of ACSS2 Expression Inhibited Tumor Xenograft Growth
(A) Spheroid growth was monitored following doxycycline-induced ACSS2 silencing in DU145 + shNTC and DU145 + shACSS2#64 cells in indicated growth
conditions. Data are presented as mean ± SEM (nR 4).
(B and C) Nude mice (nu/nu) were injected subcutaneously with DU145 (B) or BT474c1 (C) cells. Silencing of ACSS2 was initiated by providing doxycycline at the
indicated time. Each group is presented mean tumor volume ± SEM.
(legend continued on next page)
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Acetate Metabolism under Metabolic StressMS (collision-induced fragmentation) were used for molecular species identi-
fication and quantification. The identity of lipid was further confirmed by refer-
ence to appropriate lipids standards.
See also the Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
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